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Abstract
Towards New Antimalarial Drug: Depolarization of Liposomal Membranes by
Aminooxoethylcarbamothioate in the Presence of Fe3+ Ions

A thesis submitted in fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2022.

Director: Vladimir Sidorov
Professor, Department of Chemistry

Despite the efforts of scientists around the world 409,000 people died of malaria in 2019 alone.
According to the WHO 90% of those deaths occurred in Africa. Despite the high number of available
treatments, malaria continues to plague many parts of the world. This is due in part to drug resistance
developed among mosquito populations as well as limited access to medicines that do work.
Furthermore, when traveling to malaria prone areas, pretreatment with a chemoprophylaxis is common
practice. However, often the side effects to malaria pretreatment are severe. A new approach to the
treatment of malaria is a compound that is only active in the presence of Fe3+ ions and a negative
transmembrane potential (Δψ). In the parasitic stage where symptoms of malaria present, plasmodium
falciparum invades erythrocytes and increases the concentration of free Fe3+ in the cytosol of red blood
cells. The novel compound 2-(naphthalen-1-ylamino)-2-oxoethyl) (2-bromoethyl) carbamothioate is
shown to selectively lyse liposomes only under the presence of Fe3+ and a transmembrane diffusion
potential. These promising findings suggest a new type of malaria treatment that can depolarize and
selectively kill P. falciparum during the erythrocytic cycle.
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Chapter 1
Introduction
1.1

Malaria Overview

Malaria is a fatal disease caused by the Plasmodium parasites that are spread from the bite of an
infected female Anopheles mosquito.1 Of the more than 120 species of Plasmodium, five are known to
infect humans. Plasmodium falciparum is the deadliest strain and the most prominent species in Africa
while P. vivex is most prominent outside of Africa. However, Africa bears the largest burden of malaria
infections and deaths. Of the 241 million cases and 627,000 deaths worldwide in 2020, 95% of cases and
96% of deaths originate from Africa. In Africa, children under 5 account for 80% of malaria related
mortalities. To reduce the global impact of malaria, various strategies are employed. Vector control
seeks to prevent the transfer of Plasmodium from the mosquito to the human host using insecticidetreated nets (ITNs) and indoor residual sprays. ITNs have the largest impact in high transmission areas,
however their effectiveness is at risk due to increasing resistance to the pyrethroid insecticide by the
Anopheles mosquito.2 Efforts over the last 30 years to develop vaccines have been mostly unsuccessful.
The first widely used vaccine was recommended for broad use by the WHO in September of 2021.1 The
vaccine showed significant protection over a 3-4-year period in older children with 36.3 % vaccine
efficacy when given with a 20-month booster. However, the efficacy drops significantly in the much
more at-risk group of very young children (6-12 weeks old at first dose).3 Newer data also suggests that
the vaccine does not provide even efficacy across all strains furthering the need for more novel drugs to
combat the malaria crisis.4 Chemoprophylaxis is the third strategy to prevent malaria infection. Various
drugs such as doxycycline and atovaquone-proguanil are given to people traveling in malaria prone
areas, nursing mothers, and young children. However, there are many variables to consider when
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prescribing neurotoxic drugs as a chemoprophylactic. Therefore, more targeted drugs with fewer side
effects are still sought after.
1.1.1

Biology of Infection

The life cycle of the Plasmodium parasite alternates between two vectors: the female Anopheles
mosquito and vertebrate hosts. Within the vertebrate hosts, P. falciparum quickly moves from the blood
stream to the liver where they invade and infect hepatocytes. Sporozoites within the blood stream
transition from “migratory mode” to “invasive mode” upon recognition of cell surface proteins found on
the surface of hepatocytes. Upon recognition sporozoites enter the host cell and form a parasitophorous
vacuole in which they develop. While developing within the hepatocytes they undergo schizogony until
tens of thousands of daughter merozoites are released in budding packets of merosomes into the
vasculature.5 Once in the vasculature free merozoites invade erythrocytes in a fast, multi-step process
that is complete within 2 minutes. After infection of the erythrocytes is established, each merozoite
undergoes a second round of schizogony, producing 16-32 merozoites that release from the RBC,
destroying the cell membrane in the process. These merozoites are then free to infect more
erythrocytes. In a process that is still not well understood, some merozoites within erythrocytes
transition from making more asexual merozoites to form male and female gametocytes. It is these male
and female gametocytes that are necessary to complete the transmission from humans back to
mosquitoes after a female Anopheles mosquito takes a blood meal during this stage.
1.1.2

Drug Resistance

Drug resistance in malarial parasites has become a growing problem around the world. Chloroquine, the
most widely used and successful drug to treat malaria, is no longer the miracle drug it used to be. In
central Africa’s Democratic Republic of the Congo, researchers attributed the rise in both cases and
mortality to the increasing resistance to chloroquine.6 From 1982 to 1986 the proportional malaria
12

admission rate increased from 29.5% to 56.4% and the proportional malaria mortality rate increase from
4.8% to 15.3%. In 1982 there were no cases of in vivo or in vitro chloroquine-resistant malaria in the
African city of Kinshasa. By 1986, 82% of P. falciparum isolates exhibited drug resistance in vitro,
suggesting that the rise in hospital admission rates and mortality rates were directly due to this increase
in resistance.7 Other treatments, such as sulfadoxine-pyrimethamine, were used in areas of Africa where
resistance to chloroquine was high. However, resistance to this drug therapy was also developed in P.
falciparum isolates after treatment .8 While countless researchers have examined the ways in which
Plasmodium becomes resistance to new drugs, the fact remains that until effective vaccines are in broad
use, new anti-malarial drugs used for both treatment and chemoprophylaxis are in high demand.
1.1.3

Iron Metabolism

During the erythrocytic cycle of infection, merozoites undergo rapid cell division to produce
approximately 16-32 new merozoites. This process is energy intensive and requires a constant source of
fuel. Lucky for the parasite, it just happens to be within reach of a steady source of amino acids in the
form of hemoglobin. Hemoglobin represents about 95% of the soluble protein within the RBC, at a
concentration of 340 mg/mL.9 Radiolabeled amino acids within hemoglobin have been shown to be
incorporated within parasite proteins.10 However, it has also been shown that hemoglobin amino acids
serve a nonanabolic process as well. A significant portion of those amino acids are excreted by the
intraerythrocytic parasite. It has been proposed that either the parasite is making room for itself or
controlling the RBC osmotic stability.11,12 In either case, the merozoite ingests the hemoglobin through
an invagination of the parasitophorous vacuolar and parasite plasma membrane called the cytostome.
The hemoglobin is transported through this opening into an acidic food vacuole for degradation. Many
proteases are involved in breaking down hemoglobin and targeting these proteases with inhibitors has
been a strategy for antimalarial drug development. This has been met with limited success, likely due to
the redundant functions of proteases.9 After hemoglobin has been digested within the acidic vacuole,
13

the byproduct is free heme groups. As free heme is toxic to the cell due to oxygen radical catalysis, it has
to be sequestered in the form of hemozoin. Hemozoin is an inert crystal that removes the iron moiety
from solution chemistry.13 This crystalline pigment was associated with a malaria infection as early as
1849.14 Disrupting the formation of hemozoin crystals within the parasitophorous vacuole has been the
target of many antimalarials. The antimalarial quinolines such as chloroquine, quinine, and mefloquine
work by inhibiting the formation of hemozoin, leading to the toxic buildup of heme.15 These compounds
work by passively diffusing through the cell membrane and into the acidic digestive vacuole. Once in the
acidic vacuole the weakly basic amine groups on the quinolines become protonated, conferring a
positive charge on the compound and effectively trapping it within the vacuole. Trapped within the
vacuole where the degradation of hemoglobin occurs, it is able to inhibit the formation of hemozoin
leading to the toxic buildup of heme. Paradoxically Plasmodia has to synthesize its own heme rather
than use the heme broken down from its host.16 In fact, the demand for iron for the parasite is quite
high as iron is used for DNA synthesis, glycolysis, heme synthesis, etc. Therefore, Plasmodia needs
access to a labile iron pool, that is bioavailable iron is chelatable and redox active. It is still under debate
as to where the major source of this iron comes from17. However, researchers have shown that as the
parasitic cycle within the erythrocyte progresses, the labile iron pool increases. Because the need for
access to the labile iron pool is necessary for the parasite’s replication, it is viewed as a potential target
for antimalarials. Iron chelation has already been shown to inhibit erythrocytic Plasmodium in vitro and
in vivo.18 Iron chelators work by either withholding necessary iron from Plasmodia or by forming toxic
complexes with iron. In this work the latter case is examined, in which the iron chelated complex is
lethal to the Plasmodium.
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1.1.4

Intro of Novel Carbamothioate

In this study, the efficacy of the novel compound 2-(naphthalen-1-ylamino)-2-oxoethyl) (2-bromoethyl)
carbamothioate is assessed for the treatment of malaria. The carbamothioate has two unique properties
that could make it a potential antimalarial therapeutic drug; It is an amphipathic molecule with a
nonpolar naphthalene group that should be able to cross a semipermeable membrane and its polar tail
has several sites that could chelate with iron. One potential conformer is illustrated in Figure 1 in which
Fe3+ could chelate with lone pairs on either of the carbonyl groups or the sulfur atoms. However, there
are also lone pairs on both amine groups as well so other conformations that would allow iron chelation
likely exist.

Figure 1. Potential Fe3+ chelation sites with the carbamothioate.
In an erythrocyte infected with malaria, this compound should diffuse through the RBC membrane and
chelate with Fe3+. Once chelation occurs, the compound would then carry a net positive charge,
attracting it to the negatively charged cell membrane of P. falciparum. The nonpolar naphthalene tail of
the compound could then insert itself into the cell membrane of P. falciparum causing depolarization
and cell lysis and therefore parasite death. Because this compound should only work in the presence of
free Fe3+ and be attracted to a negatively charged membrane, it should be highly selective. Furthermore,
the resting transmembrane potential of a plasmodia parasite is approximately -90 mV while for an
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erythrocyte it’s only -10 mV19, 20. This large difference in potentials offers yet another avenue of
selectivity to potentially exploit. To test whether this novel compound could depolarize a cell membrane
under both a transmembrane potential and in the presence of Fe3+ ions, liposomes were used as a
model for the Plasmodia parasite. Liposomes were made with an internal buffer containing a high
concentration of potassium relative to the external buffer they are suspended in so that a negative
transmembrane potential could be generated using a selective potassium transporter. They were also
prepared with an internal dye, HPTS, used to monitor the integrity of the liposomes. Two primary assays
were used in assessing the liposome integrity. First, Safranin O was used to determine whether a
transmembrane potential can be applied across the membrane of the liposome, and secondly, whether
the liposomes hold up under that transmembrane potential. The transmembrane potential was
generated using valinomycin. Valinomycin, shown in Figure 2, is a selective potassium transporter that
diffuses freely through lipid membranes.

Figure 2. Structure of Valinomcyin.
Valinomycin contains a pore in the center that is over 10,000 times more selective for potassium ions
than sodium.21 Since the internal buffer contains a higher concentration of potassium relative to the
external buffer, valinomycin transports the potassium down its concentration gradient to the external
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buffer generating a negative transmembrane potential. To measure this potential, Safranin O is used.
Safranin O works by changing the intensity of its absorbance as a function of a transmembrane
potential.22 Safranin O has been shown to stack upon induction of a transmembrane potential and that
results in a spectral shift that is linearly related to a transmembrane potential. Using the spectral shift of
Safranin O, one can monitor the development of a transmembrane potential generated by valinomycin
and determine how stable the liposome is under those conditions. However, due to fluorescent
quenching of Safranin O by iron, the depolarization experiments in the presence of iron were not
compatible with Safranin O. Instead, HPTS was used to indirectly measure depolarization of liposomes.
HPTS, shown in figure 3, is a pH sensitive dye that has two unique fluorescent signatures from its
unprotonated and protonated forms. This allows one to change the pH of the external buffer and
monitor the liposome structural integrity as a function of those pH changes. As the HPTS dye is within
the liposome, changes to the pH should not affect the internal dye in stable liposomes.

Figure 3. Fluorescent dye HPTS.
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Methodology

2.1 Compound Synthesis
The following synthesis is depicted in figure 4 below. 210 mg of 1-napthylisothiocynante were added to
a 100 mL round bottom flask. To the flask, 12 mL of acetonitrile was added and the mixture was stirred
until dissolved. To the flask, 70 µL of ethanolamine were added and the mixture was stirred with a
magnetic stir bar for approximately 4 hours. Then 120 µL of triethylamine were added and stirred for
approximately 10 minutes. After this time the flask was put on ice. An addition of 103 µL of
bromoacetylbromide was mixed with 2 mL of acetonitrile and put on ice until chilled. This mixture was
then very slowly added to the flask and allowed to stir on ice for approximately 4 hours. This mixture
was heated at reflux at 75 ° C for approximately 4 hours. After reflux, the flask was allowed to cool and
placed on a rotovap to remove solvent. The crude was weighed and dissolved in approximately 2 mL of
87:13 DCM:EtOAc. A sample of crude was submitted to LC-MS analysis before purification. The crude
was then purified on a packed silica gel column using 87:13 DCM:EtOAc as eluent. The purified product
was collected in fractions, tested via TLC, and then all fractions containing the compound of interest
were combined. The combined purified product was then dried to a neat material, weighed, and then
tested via NMR for purity.
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Figure 4. Synthetic Scheme
2.2 Solution Preparation
•

Buffer A (pH 6.4, 100 mM NaCl): 0.8824 g of NaH2PO4, 0.3761 g of Na2HPO4, and 5.8405 g NaCl
were added to a 1 L volumetric flask and diluted to volume with type 1 water.

•

Buffer B (pH 6.4, 100 mM KCl): 0.8827 g of NaH2PO4, 0.3757 g of Na2HPO4, and 7.4508 g KCl
were added to a 1 L volumetric flask and diluted to volume with type 1 water.

•

100 µM HPTS dye: 192 mgs of HPTS were added to a 10 mL volumetric flask and diluted to
volume with buffer B. A 683 µL aliquot of this solution was then added to a 25 mL volumetric
flask and diluted to volume with buffer B.
19

•

Triton-x25: Triton-x100 was diluted 1:4 with DI water

•

3.75 µM Valinomycin in DMSO: 20 mgs of valinomycin were diluted into 25 mL of DMSO. Then a
521 µL aliquot was diluted to 10 mL with DMSO.

•

0.5 M NaOH(aq): 0.1120 g of NaOH was dissolved into 5.6 mL of Type 1 water.

2.3 Liposome Synthesis
Egg yolk L-α-phosphatidylcholine (EYPC ethanol solution, 120 µL, 79 µmol) was dissolved in
chloroform/methanol solution, evaporated under reduced pressure until a thin lipid cake coated all
sides of the round bottom flask. It was then dried under high vacuum for 2 hours. The lipid film was then
hydrated with 1,200 µL of 100 µM HPTS dye in buffer B. Seven freeze/thaw cycles were performed using
a dry ice acetone bath and a 50 °C water bath. The resulting suspension was subjected to 21 highpressure extrusions through a 0.1 µm polycarbonate membrane at room temperature. Through sizeexclusion chromatography (SEC) using G-75 Sephadex, the extra-vesicular buffer with HPTS was replaced
with buffer A to a concentration of 11 mM.

2.4

Fluorometric experiments:

All fluorometric measurements were performed at 15 °C using a Flouromax 3 (Jobin-Yvon/Horriba)
spectrophotometer.
2.4.1

Safranin O potential buildup:

Liposomes were diluted in buffer A containing 60 nM Safranin O to a liposome concentration of 550 µM
and placed in a quartz cuvette under gentle stirring. Fluorescent emission was monitored at 580 nm
with excitation at 520 nm. At 100 seconds the cuvette was spiked with 20 µL of 3.75 µM valinomycin. At
800 seconds 20 µL of buffer B was spiked into the cuvette. The fluorescence was monitored until 1000
seconds.
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2.4.2

8-Hydroxypyrene-1,3,6-trisulfonic acid (HPTS) Experiments:

HPTS experiments were conducted by diluting the liposomes into buffer A to make a liposome
concentration of 550 µM. The excitation wavelengths for the protonated and unprotonated HPTS were
set at 405 nm and 460 nm respectively and both emission wavelengths were monitored at 508 nm. If
iron was added, 62.5 µL of 0.5 mM FeCl3 in buffer A was added before the run. If added, 20 µL of 3.75
µM valinomycin in DMSO was added at 60 seconds. Either DMSO for blanks or our compound was
spiked at varying concentrations noted in Table 1 at 200 seconds. In fluorimetry experiments 26.3 µL of
0.5 M NaOH is added. Finally, 50 µL of triton-x25 is added at 600 seconds. Emission spectra is recorded
until 800 seconds.
To convert the raw data of both traces (protonated HPTS and deprotonated) the response of
deprotonated HPTS is divided by protonated. This gives a ratio of deprotonated to protonated HPTS. The
average is then normalized to zero using data from 0-59 seconds as this is before the addition of any
compounds and sets the baseline to zero. The maximum ratio is then normalized to 100 by dividing each
response by the maximum response and multiplying by 100. This sets the baseline to zero and the
maximum response ratio to 100. This allows each run to be compared more accurately.

Table 1. Spiking regime for HPTS fluorescence
Run

0.5 mM FeCl3 (aq)

Valinomycin 3.75 µM

Drug/DMSO

Double Blank

-

-

50 µL DMSO

No Fe, no Val

-

-

10 µM drug

Val, no Fe

-

62.5 µL

10 µM drug

Fe, no Val

62.5 µL

-

10 µM drug

Fe and Val

62.5 µL

62.5 µL

10 µM drug
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2.5 Vapor Pressure Osmometry (VPO) analysis:
VPO analysis was performed by weighing out FeCl3 and our compound. Each was diluted to the
concentrations noted in Table 2 in and Table 3. A 10 µL aliquot of sample was added onto a filter paper
that was then inserted into the Wescor VAPRO analyzer and analyzed for vapor pressure. Prior to
analysis the VPO was calibrated with premade stock NaCl(aq) standards at 100, 270, and 1,000 mmol/kg.
Microosmolality was calculated by dividing the weight of the sample by the molecular weight,
multiplying the number of ions that compound generates (1 for carbamothioate and 4 for FeCl3) and
multiplying by 100,000.

2.6 Dynamic Light Scattering (DLS) studies:
DLS studies were conducted using a Malvern Zetasizer ZS. Sample were weighed and diluted in 70:30
THF:H2O. They were then filtered through a 0.45 PTFE filter, sonicated, and aliquoted into a quartz
cuvette and placed within the Zetasizer. All samples were equilibrated for 5 minutes prior to DLS
measurements and conducted at 25 °C. Carbamothioate was prepared at 4 mg/mL in all runs for a
concentration of 11 mM. FeCl3 was prepared at 24.15 mg/mL for a concentration of 150 mM.
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Results and Discussion
3.1

Compound synthesis.

Before the sample was purified via silica column chromatography, a 5 mg sample was submitted to the
MassSpec department at VCU for LC-MS analysis. The total ion chromatogram in Figure 5 shows two
prominent peaks at m/z 389 and 391. These peaks represent the decyclized product with a sodium
adduct[M+22]+. Two peaks are present because the compound contains bromine at equal isotopic
abundances. Two peaks of compound are also present at 405 and 407 in which it is forming an adduct
with potassium, [M+39]+. The peak at 287, [M+1] represents the other isomer from step 2 of the
synthesis. This product cannot undergo decyclization and is separated upon silica column
chromatography. After purification the compound was tested via NMR as shown in figure 6 and
compared to values obtains from Franklin, C., et al. illustrated in Figure 7.23 As each chemical shift in the
NMR in figure 6 matched the literature NMR that was obtained from Dr. Constance Franklin, it was
determined that the compound had been successfully synthesized and purified.

r200204r01 #1-50 RT: 0.00-0.40 AV: 50
T: FTMS + p NSI Full ms [100.00-1000.00]
229.0859
100

NL: 1.19E7

95
287.0931

90
85
80
75
70

Relative Abundance

65
391.0021

60
55

406.9764

50
45
40
35
30
25
309.0754

20
15

457.2846

213.1085
169.0809

515.1719

139.0542
10

332.3408
555.1681

5

595.1004
0
200

300

400

500

600

662.2514 702.3410
700

807.0460
800

m/z

Figure 5. TIC of crude from synthesis prior to silica column chromatography.
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Figure 6.1H NMR of carbamothioate in DMSO-d6 at 400 MHz

Figure 7. Literature 1H NMR of carbamothioate in DMSO-d6 at 400 MHz
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3.2

Liposome potential induction measured by Safranin O

In this study liposomes were used to model the conditions of a Plasmodia parasite within an infected
erythrocyte. The conditions the carbamothioate would target the membrane were with free Fe3+ in
solution and a negative transmembrane potential. However, to first determine the capacity of the
liposomes to generate a potential in the presence of valinomycin, Safranin O was used. Safranin O, as
shown in Figure, 8 is a cationic dye that without the positive charge would be hydrophobic. However,
due to that positive charge on the tertiary amine, the compound is water soluble. When in solution with
a lipid membrane the Safranin O stays in the aqueous phase. Then when a negative charge potential is
generated across the lipid membrane, the Safranin O partitions into the hydrophobic membrane and
starts to stack. This stacking results in an increase in emission intensity that is directly related to the
charge applied across the membrane. As illustrated in Figure 9, when the selective potassium
transporter valinomycin is added to solution, the emission spectra spikes. Because the concentration of
K+ is higher inside the liposome, when the valinomycin is added, it captures K+ ions and shuttles it down
its concentration gradient to the extravesicular solution generating a negative transmembrane
potential. The equilibrium between charge and concentration is quickly met and the potential remains
consistent until the addition of potassium buffer.
Two important pieces of information were concluded from this experiment. First, the liposomes were
able to generate a potential across the lipid membrane. Secondly, after that initial buildup of charge, the
slope of the intensity remains at zero. This illustrates that the liposomes are stable under the
transmembrane potential that is generated. Later experiments seek to perturb the liposomes and
determining that valinomycin and a transmembrane potential alone aren’t enough to cause liposomal
lysis is necessary to validate those experiments.
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Figure 8. The cationic dye Safranin O.
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Figure 9. Liposomes with internal KCl buffer suspended in extravesicular NaCl buffer. λexc = 520 nm, λem =
580 nm. At 60 seconds the selective K+ transporter valinomycin is added. At 840 seconds external KCl
buffer is added.
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3.3

Results from HPTS fluorometry.

The HPTS fluorescent dye within the liposome was used to indirectly measure the liposome integrity. As
intravesicular dye within the liposome should not be affected by changes to the pH of the extravesicular
solution, so any amount of deprotonation events can be seen as the liposomes becoming less stable
and/or undergoing lysis. This allows one to determine if the carbamothioate is able to effectively
destabilize and/or depolarize the liposomes under certain conditions.
A typical double blank run, as shown in figure 10, starts with liposomes with intravesicular HPTS dye
and KCl buffer suspended in dye-free NaCl buffer. Both protonated and deprotonated HPTS fluorescence
are monitored in the spectrophotometer. At this point the intravesicular and extravesicular pH is 6.4 and
the baseline is set to 0. DMSO is spiked into the cuvette at 200 seconds with minimal changes in the
baseline. At 300 seconds 26.3 µL of 0.5 M NaOHaq is added. In all experimental runs, including the
blanks, some amount of HPTS is deprotonated. However, when compared to other experimental runs,
the level of deprotonation remains constant as illustrated by the flat lines between 300 seconds and 600
seconds in which trition-x25 is added. At 600 seconds, upon the addition of the surfactant triton, all
liposomes lyse and release the intravesicular dye exposing it to the basic solution and causing the ratio
of deprotonated to protonated HPTS to reach its maximum value. Therefore, to compare the efficacy of
the carbamothioate, the amount and rate of deprotonation events that occur between 300 and 600
seconds is compared between experiments. The yellow trace in Figure 10 that represents the double
blank with no FeCl3, no valinomycin, and DMSO shows the flattest baseline between 300 and 600
seconds illustrating the least amount of deprotonation events. The grey trace in which carbamothioate
is present at 10 µM does increase slightly, indicating a slight capacity to perturb the liposomal
membrane without either a transmembrane potential or free Fe3+. This is also seen in the run (dark blue)
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in which valinomycin is added without iron indicating slight activity in the presence of membrane
potential alone. However, as the membrane potential of plasmodia is much higher than the erythrocyte
in which it is inhabiting, this still favors the carbamothioate to target the parasite. The orange trace, in
which FeCl3 is present without valinomycin also shows depolarization potential indicating that iron
chelation alone is sufficient to generate compound activity. However, the trace with the steepest slope,
indicating the highest deprotonation rate, is the run in which both iron and valinomycin are present
shown in the light blue trace in Figure 10. This suggests that the novel compound is able to most
effectively target the membrane in conditions that are most similar to those found within a malaria
infected erythrocyte. The fluorimetry study in Figure 11 illustrates another promising property of the
compound, dose dependency. In this example, both the double blank (DMSO without valinomycin) and
the blank (DMSO with valinomycin) exhibit flat baselines between 300 and 600 seconds. However, as
the concentration of carbamothioate is increased, the rate of deprotonation increases. With each
increasing dose, not only does the total amount of deprotonated HPTS increase, the slope of the line
between 300 and 600 seconds also increases. This illustrates a clear dose-dependent response.
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Figure 10. Liposome integrity monitored with and without valinomycin, Fe3+, and carbamothioate.
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Figure 11 Dose dependent response monitored by HPTS fluorescence.

3.4

Vapor Pressure Osmolality.

The VPO results shown in Figures 12-14 were used to determine the relationship between Fe3+ and the
carbamothioate. Based off the structure of the compound it was hypothesized that it would chelate with
iron. Using that information, it was hypothesized that the vapor pressure of a solution containing both
iron and carbamothioate would be less than the sum of individual solutions of iron and carbamothioate.
Vapor pressure is a colligative property based solely on the number of individual solutes in a solution. If
Fe3+ and the compound chelate together in solution that reduces the total number of solutes and
therefore the vapor pressure should be less than the respective sums of the Fe3+ and compound alone.
To test this, three solutions at differing concentrations of FeCl3 and compound were analyzed via VPO in
a solution of 90:10 THF:H2O. The results of the individual readings were then used to calculate the
theoretical vapor pressure of a solution containing both carbamothioate and FeCl3 assuming no
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interaction/chelation. This was done by subtracting the solvent blank vapor pressure from the vapor
pressure results of either FeCl3 or compound alone. An example calculation for the theoretical vapor
pressure of a solution containing both FeCl3 and carbamothioate is illustrated in Equation 1.

VPOtheo=(FeCl3 VPOraw- Solvent) + (Carbamothioate VPOraw- Solvent) + Solvent

Equation 1

Using this formula, one can determine what the theoretical vapor pressure of a solution containing both
FeCl3 and carbamothioate if they do not interact and exist as individual solutes in solution. Results of
raw VPO and theoretical vapor pressure calculations are shown in Table 2. These values were then
plotted in Excel using microosmolality on the x-axis and the instrument vapor pressure reading in mmol
solute/kg of solvent on the y-axis. As shown in Figure 12, there was an enhanced instead of reduced
response when the VPO was taken of both FeCl3 and the carbamothioate.
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Figure 12. VPO of FeCl3, carbamothioate, combination, and theoretical in 90:10 THF:H2O
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Table 2. VPO values for compound, iron, combination, and theoretical in 90:10 THF:H2O
Iron (µsol/mL)
247
123
61.6
54.5
27.2
13.6

Compound
(µsol/mL)
54.5
27.2
13.6
247
123
61.6

VPOraw (mmol/kg)

VPOCor (mmol/kg)

VPOTheo (mmol/kg)

76
322
163
115
184
123
101
745
329
133

0
246
8
39
108
47
25
669
253
57

430
210
140

One potential explanation was that there was not enough water in the 90:10 THF:H2O solution and that
iron was experiencing limited solubility. It was surmised that when mixed with the carbamothioate it
enhanced the solubility of the FeCl3, increasing the number of solutes in solution, thereby increasing the
vapor pressure reading. To test this, the experiments were repeated in a solution of 70:30 THF:H2O to
ensure full solubility of the FeCl3. This solution presented its own unique problems; Increasing the
concentration of carbamothioate did not result in an increasing vapor pressure and there was still an
enhanced vapor pressure greater than the sum of each individual solution as shown in Figure 13.
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Figure 13. VPO of FeCl3, carbamothioate, and combination in 70:30 THF:H2O.

The compound was fully solubilizing as there was no turbidity or cloudiness in solution and as the
increasing concentration of iron resulted in a clear linear increase in vapor pressure, the limited
solubility theory didn’t hold up. It was then hypothesized that the compound was forming micelles in
the THF:H2O mixtures. This would explain no increases in vapor pressure reading as the compound
concentration increases. The total number of individual solutes would not increase as concentration
increases if they are congregating in micelles. Also, the enhanced vapor pressure reading when in
combination with the FeCl3 can also be explained with micelle formation. If the compound does indeed
chelate Fe3+, then the micelles that formed would be disrupted by the Fe3+ in solution. As the Fe3+
chelates with the polar tail of the compound, the accumulating positive charge on the micelles would
begin to repel each other, causing the micelle to break apart, increasing the number of individual solutes
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in solutions and thereby increasing the vapor pressure. To test this hypothesis, the vapor pressure of
compound was tested at a steady concentration while increasing the concentration of iron only. Those
same concentrations of FeCl3 that were used in combination with the compound were then individually
tested at those exact concentrations and subtracted from those values from the combination of both
FeCl3 and compound. Raw vapor pressure values from these experiments are described in Table 3. In
this way, one can determine that the vapor pressure was increasing as a result of the increase in Fe3+
concentration, even after correcting for the contribution from that the FeCl3. As shown in Figure 14, this
was true at all four concentrations of compound. In all cases, increasing the iron concentration resulted
in increased vapor pressure. This was attributed to the micelles breaking down with each addition of
FeCl3. To begin to characterize the size and formation of potential micelles, VPO experiments were not
enough.
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Figure 14. VPO of compound at various FeCl3 concentrations.
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Table 3. VPO values of carbamothioate with varying Fe concentrations

3.5

Iron (µsol/mL)

Compound (µsol/mL)

VPOraw (mmol/kg)

VPOCor (mmol/kg)

128

-

101

-

85.8
64.4

-

95
95

-

128
85.8

7.26
7.26

152
120

51
25

64.4
128

7.26
21.1

110
142

15
41

85.8
64.4

21.1
21.1

131
117

36
22

128
85.8

72.6
72.6

245
215

144
120

64.4
128
85.8
64.4

72.6
132
132
132

185
303
247
211

90
202
152
116

Dynamic Light Scattering

The VPO experiments strongly suggested the formation of micelles. However, to confirm their presence,
dynamic light scattering (DLS) was used to determine the particle size of potential micelles. The solvent
blank in Figure 15 shows just one peak at approximately 7 nm. This peak shows up in all of the DLS
experiments and is likely an artifact of the THF:H2O solvent. When looking at the compound in solution
at 4 mg/mL there is another peak at approximately 700 nm illustrated in Figure 16. This peak potentially
represents the micelles forming in solution. However, because larger particles scatter light much more
than smaller particles, the peak at 700 nm is present in much lower concentrations than the peak at 6.5
nm as the intensity of scattering of a particle is proportional to the sixth power of its diameter24. If these
are the micelles of the carbamothioate, then the VPO data suggests that adding FeCl3 would cause those
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micelles to break apart and the peak at 700 nm to go away. To look at the outcome of adding the FeCl3
to the carbamothioate solution the DLS of FeCl3 was first taken. Figure 17 shows the same peak present
in all samples plus an additional peak at approximately 100 nm. As this doesn’t overlap with the
potential micelle peak at 700 nm the DLS particle size measurements of compound with varying amount
of FeCl3 were able to be conducted. As shown in Figures 18 and 19, as the concentration of Fe3+ in
solution increases, the peak at approximately 700 nm decreases in intensity until it goes away all
together. This strongly supports the theory that the compound is indeed forming micelles and that these
micelles break up in the presence of Fe3+. This makes perfect sense, as the concentration of Fe3+
increases, more and more Fe3+ ions chelate with the compound on the surface of the micelle. As these
positive charges accumulate, the coulombic repulsion is greater than the intermolecular bonds keeping
the micelle together and the newly chelated Fe-carbamothioate complex breaks away from the micelle
until the micelle is fully broken apart.

Figure 15. DLS of Solvent blank (70:30 THF:H2O).
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Figure 16. Carbamothioate in 70:30 THF:H2O at 11 mM.

Figure 17. DLS of solvent with FeCl3 (3.75 mM).
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Figure 18. Carbamothioate (11 mM) with FeCl3 (3.65 mM).

Figure 19. Carbamothioate (11 mM) with FeCl3 (7.14 mM).
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4.0

Future Work

Now that it’s been shown that the carbamothioate is most active in the presence of Fe3+ and with a
transmembrane potential, the next step will be to see how the compound works with cells in vitro. Cell
viability assays will be performed by dosing cells of a similar transmembrane potential to that of
Plasmodia with the carbamothioate and cotreatment with FeCl3 at varying concentrations and without
any FeCl3 at all. If cells remain viable in the presence of compound and no FeCl3 but show substantial cell
death in those treated with both, then that would provide evidence of the selectivity of our compound.
Furthermore, by running various viability assays at different FeCl3 concentrations, one could then
determine the “lethal” amount of FeCl3 required. Ideally this would be within the iron concentrations of
erythrocytes that have an active malaria parasitic infection. However, if the iron requirements are too
high and aren’t physiologically relevant, the next step would be to increase the active concentration of
the compound without having to increase the dose. This may be achieved by linking two or more
carbamothioate molecules onto one linker molecule. A proposed reaction would be the Williamson
ether synthesis reacting a linker molecule with multiple hydroxyl groups such as propylene glycol, and
base to perform two SN2 reactions on the bromine of each compound to link them together. A proposed
reaction is presented in Figure 20 with propylene glycol. However, there are many options that may be
explored to best optimize the compounds effectiveness.

Figure 20. Proposed synthetic route with propylene glycol.
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5.0

Conclusion

The need for a new type of antimalaria therapeutic is without question. In this work we’ve shown that
the novel compound carbamothioate possesses unique properties that allow it to target an infected
erythrocyte. The conditions in which our compound is active should only be present within an actively
infected erythrocyte conferring great specificity. We’ve demonstrated not only a dose dependent
response, but a response that is maximized when there is a negative transmembrane potential and free
Fe3+. Due to the unique structure of our compound, drug resistances found in Plasmodia populations
would not likely confer resistance to this compound. Furthermore, the formation of micelle in aqueous
media could also be used to this drugs advantage. Micelles lower the working concentration of a
circulating drug thus lowering potential off-target toxicities and can deliver a more concentrated dose
when the right conditions are met. In conclusion, in this work we present a novel anti-malarial
therapeutic with great potential.
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